- Report
- April 2025
- 161 Pages
Asia Pacific
From €3072EUR$3,450USD£2,674GBP
- Report
- April 2025
- 142 Pages
North America
From €3072EUR$3,450USD£2,674GBP
- Report
- April 2025
- 150 Pages
Africa, Middle East
From €3072EUR$3,450USD£2,674GBP
- Report
- June 2025
- 300 Pages
Latin America
From €3445EUR$3,869USD£2,999GBP
- Report
- August 2025
- 101 Pages
Europe
From €3517EUR$3,950USD£3,062GBP
- Report
- August 2025
- 90 Pages
North America
From €3072EUR$3,450USD£2,674GBP
- Report
- August 2025
- 80 Pages
Africa, Middle East
From €3072EUR$3,450USD£2,674GBP
- Report
- August 2025
- 98 Pages
Asia Pacific
From €3517EUR$3,950USD£3,062GBP
- Report
- June 2025
- 95 Pages
Asia Pacific
From €3517EUR$3,950USD£3,062GBP
- Report
- June 2021
- 123 Pages
Global
From €1155EUR$1,297USD£1,005GBP
- Report
- July 2020
- 269 Pages
Global
From €3114EUR$3,497USD£2,711GBP
- Report
- August 2019
- 264 Pages
Global
From €3557EUR$3,995USD£3,097GBP
- Report
- January 2025
- 252 Pages
China
From €4273EUR$4,799USD£3,720GBP
- Report
- August 2024
- 381 Pages
Global
From €4273EUR$4,799USD£3,720GBP
- Report
- February 2023
- 336 Pages
Global
From €4273EUR$4,799USD£3,720GBP
- Report
- January 2023
- 270 Pages
Global
From €4273EUR$4,799USD£3,720GBP
- Report
- September 2022
- 799 Pages
Global
From €4273EUR$4,799USD£3,720GBP
- Report
- April 2019
- 850 Pages
Global
From €4006EUR$4,499USD£3,488GBP
- Report
- May 2024
- 343 Pages
Global
From €4273EUR$4,799USD£3,720GBP
- Report
- September 2024
- 972 Pages
Global
From €4273EUR$4,799USD£3,720GBP

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases.
Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field.
The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more